---
title: "RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases"
description: "RetinalGenix Technologies Inc. has contracted Seer, Inc. to enhance early detection of neurodegenerative and retinal diseases. The collaboration will integrate RetinalGenix’s retinal imaging technolog"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261400908.md"
published_at: "2025-10-16T09:01:20.000Z"
---

# RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases

> RetinalGenix Technologies Inc. has contracted Seer, Inc. to enhance early detection of neurodegenerative and retinal diseases. The collaboration will integrate RetinalGenix’s retinal imaging technology with Seer’s proteomic profiling platform to identify biomarkers for conditions like Alzheimer’s, Parkinson’s, and diabetic retinopathy. The partnership aims to accelerate diagnostic innovation and broaden early-detection solutions in clinical and home care settings.

RetinalGenix Technologies Inc. announced that it has entered into a contract with Seer, Inc., a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix’s ultra-high-resolution retinal imaging technology with Seer’s proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer’s disease, Parkinson’s disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [SEER.US - Seer](https://longbridge.com/en/quote/SEER.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 05:30 ET 真实世界证据：后胫腱退化患者的疼痛和功能评分有所改善 | 来自大学足踝研究所和再生实验室的医生发表了一项经过同行评审的研究，探讨了脐带结缔组织同种异体移植物用于治疗对保守治疗无反应的后胫腱退化（PTTD）患者。研究显示，接受同种异体移植物的患者在疼痛和生活质量方面有显著改善，且未报告不良事件。这些 | [Link](https://longbridge.com/en/news/275740095.md) |
| 威斯康星大学麦迪逊分校要求学生报告麻疹疫苗接种情况 | 威斯康星大学麦迪逊分校已要求学生披露其麻疹、腮腺炎和风疹等疾病的疫苗接种状态，此举是在校园内出现近期麻疹病例后实施的。该政策旨在增强公共健康意识，并为高风险学生提供更好的支持。此公告是在全国麻疹病例增加的背景下发布的，卫生官员呼吁进行疫苗接 | [Link](https://longbridge.com/en/news/275930065.md) |
| UT Health San Antonio 宣布长期支持者 Bill 和 Rebecca Reed 向 Biggs 研究所捐赠 500 万美元 | 德克萨斯大学圣安东尼奥分校获得了比尔和丽贝卡·里德的 500 万美元捐款，以支持格伦·比格斯阿尔茨海默病与神经退行性疾病研究所。这笔资金将建立比尔和丽贝卡·里德精准治疗与支持护理基金，增强对痴呆症的研究和患者护理。该研究所旨在应对南德克萨斯 | [Link](https://longbridge.com/en/news/275800732.md) |
| 被忽视的致命疾病：黑热病在肯尼亚激增 | 肯尼亚报告了 kala-azar 疾病病例激增的情况，感染人数从 2024 年的 1,575 例上升至 2025 年的 3,577 例。这种由沙蝇传播的疾病如果不治疗，致死率高达 95%。60 岁的祖母 Harada Hussein Abd | [Link](https://longbridge.com/en/news/275215422.md) |
| 研究发现，肥胖会使因感染而住院或死亡的风险增加 70% | 一项新的研究显示，肥胖个体住院或因感染死亡的可能性增加 70%。研究人员分析了来自芬兰超过 67,000 名成年人和来自英国生物银行的 470,000 名成年人健康数据，发现肥胖与全球感染相关死亡人数显著相关。该研究强调了制定促进健康生活方 | [Link](https://longbridge.com/en/news/275645321.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.